HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by DeBellis, R. J. Search for Related Content PubMed PubMed Citation Articles by DeBellis, R. J.

RONALD J. DEBELLIS, PHARM.D., FCCP, is Chair and Professor of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences–Worcester, 19 Foster Street, Worcester, MA 01608 (rjdebellis{at}wor.mcphs.edu).

Purpose. The incidence, etiology, impact, and management of anemia in critical care patients and the development of treatment guidelines and protocols for the management of anemia in this patient population are discussed. Summary. Most patients in intensive care units develop anemia as a result of blood losses, nutritional deficiencies, hemolysis, myelosuppression, renal insufficiency, inflammation, infection, or another disease process. Anemia can have an adverse impact on critically ill patients with severe ischemic heart disease or cerebrovascular disease and patients undergoing surgery. The use of blood conservation measures and restrictive blood transfusion strategies can circumvent problems associated with transfusion. Epoetin alfa increases hemoglobin concentrations and reduces the need for transfusion in critical care patients, including surgical patients with large anticipated blood losses. Epoetin alfa also appears to be effective for managing anemia in patients with multiple organ dysfunction syndrome. Iron supplementation is needed by most patients receiving erythropoietic therapy. Iron supplementation without erythropoietic therapy is inadequate to correct anemia unrelated to iron deciency. Concerns have been raised about a possible increased risk for infection when parenteral iron therapy is used in critical care patients. Developing treatment guidelines or protocols for managing anemia in critical care patients can minimize the need for transfusions and improve prescribing of erythropoietic therapy. Conclusion. Epoetin alfa can play an important role in managing anemia in critical care patients, thereby minimizing patient exposure to transfusion-related risks and optimizing the use of the limited blood supply. There is currently no data available for use of darbepoetin in this manner. Index terms: Anemia; Blood; Combined therapy; Critical illness; Epoetin alfa; Hematopoietic agents; Infections; Iron preparations; Protocols; Toxicity

 

This article has been cited by other articles:

				M. W. Kruse and J. L. Lee Questionable conclusions about epoetin alfa Am. J. Health Syst. Pharm., September 1, 2007; 64(17): 1789 - 1791. [Full Text] [PDF]